EAACI Congress 2025
BackOAS09 - Progress in understanding the mechanisms of airborne allergen immunotherapy
Saturday 14 Jun, 15:00 PM -
16:30 PM Glasgow, United Kingdom
Carron 1
Oral Abstract Sessions
15:00
Subcutaneous AIT with a thermosensitive hydrogel formulation containing genetically engineered Bet v 1 is safe and induces a strong protective immune response in birch pollen allergic patients
15:12
Modulation of allergen-specific type 2 memory B cells over the course of 18 months sublingual immunotherapy for house dust mite allergy
15:24
The Skin Sebum and Moisture Levels of Children with Allergic Diseases: How Predictive Are They for House Dust Mite Allergy?
15:36
Effectiveness of allergy immunotherapy on symptom-relieving medication use: Results from the Real world Evidence of aLlergy immunotherapY (RELY) study
15:48
Effectiveness of allergy immunotherapy on asthma medication use and asthma exacerbations: Results from the Real world Evidence of aLlergy immunotherapY (RELY) study
16:00
Individual Differences in Response to Dust-Mite-Allergen Specific Immunotherapy in Allergic Rhinitis: A Meta-analysis of Randomized Controlled Trials
16:12
Glutaraldehyde Cross-linking Stoichiometry: Impact on Structure, IgE Binding and Allergenic Activity of Betula verrucosa Pollen Extracts
